Xanthine Oxidoreductase Inhibitor Use Associated With Reduced Risk of Sarcopenia and Severe Sarcopenia in Patients Undergoing Hemodialysis

BACKGROUND: Xanthine oxidoreductase (XOR) inhibition reduces reactive oxygen species (ROS) production and enhances adenosine triphosphate (ATP) synthesis. We investigated the protective effects of XOR inhibitor treatment on sarcopenia, frequently observed in patients undergoing hemodialysis (HD), in...

Descripción completa

Detalles Bibliográficos
Autores principales: Kurajoh, Masafumi, Mori, Katsuhito, Miyabe, Mizuki, Matsufuji, Shota, Kizu, Akane, Tsujimoto, Yoshihiro, Emoto, Masanori
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8859856/
https://www.ncbi.nlm.nih.gov/pubmed/35198574
http://dx.doi.org/10.3389/fmed.2022.817578

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8859856/
https://www.ncbi.nlm.nih.gov/pubmed/35198574
http://dx.doi.org/10.3389/fmed.2022.817578

Ejemplares similares